Skip to Content
MilliporeSigma
  • Aldehyde Dehydrogenase, a Therapeutic Target in Chordoma: Analysis in 3D Cellular Models.

Aldehyde Dehydrogenase, a Therapeutic Target in Chordoma: Analysis in 3D Cellular Models.

Cells (2021-03-07)
Marie-Anaïs Locquet, Anne-Lise Dechaume, Paul Berchard, Lhorra Abbes, Daniel Pissaloux, Franck Tirode, Inès Ramos, Julie Bedoucha, Julie Valantin, Marie Karanian, Raul Perret, Olivier Gille, Jean-Yves Blay, Aurélie Dutour
ABSTRACT

Chordomas are rare, slow-growing tumors of the axial skeleton. These tumors are locally aggressive and refractory to conventional therapies. Radical surgery and radiation remain the first-line treatments. Despite these aggressive treatments, chordomas often recur and second-line treatment options are limited. The mechanisms underlying chordoma radioresistance remain unknown, although several radioresistant cancer cells have been shown to respond favorably to aldehyde dehydrogenase (ALDH) inhibition. The study of chordoma has been delayed by small patient cohorts and few available models due to the scarcity of these tumors. We thus created cellular 3D models of chordoma by using low-adherence culture systems. Then, we evaluated their radiosensitivity using colony-forming and spheroid size assays. Finally, we determined whether pharmacologically inhibiting ALDH increased their radiosensitivity. We found that 3D cellular models of chordoma (derived from primary, relapse, and metastatic tumors) reproduce the histological and gene expression features of the disease. The metastatic, relapse, and primary spheroids displayed high, medium, and low radioresistance, respectively. Moreover, inhibiting ALDH decreased the radioresistance in all three models.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Alcian Blue solution, 1% in 3% acetic acid, pH 2.5
Sigma-Aldrich
Crystal Violet Solution, 1%, aqueous solution